Autologous stem cell transplantation in myeloma: the St James’s Hospital experience, 1997–2003
- 25 Downloads
High-dose treatment with autologous stem cell transplantation (ASCT) has become the standard of care for patients with myeloma below the age of 65 years.
We report an audit of 60 patients (median age: 52.5 years) who underwent ASCT in the National Bone Marrow Transplant centre in St James’s Hospital in Dublin between 1997 and 2003 inclusive.
Clinical and laboratory data were retrieved from patient medical records and hospital information management systems.
Thirty-six patients had IgG, 11 IgA, 1 IgD, 9 light chain and 3 non-secretory MM. Fifty-seven (95%) patients received anthracycline-corticosteroid combination chemotherapy prior to autografting. There was no transplant-related mortality (TRM). Complete (CR) and Partial Responses (PR) were seen in 16 (29.6%) and 29 (53.7%) of those evaluable (n = 54 (90%)). The actuarial Progression-Free (PFS) and Overall Survival (OS) rates at five years are 13% and 55% respectively.
Centre outcome is comparable to published international series and supports the use of ASCT in the treatment of this malignancy.
- 2.MRC Working party on Leukaemia in Adults. Report on the second myelomatosis trial after 5 years of follow-up.Br J Cancer 1980; 42: 813–22.Google Scholar
- 3.Myeloma Trialists’ Collaborative Group. Combination chemotherapy versus Melphalan and Prednisolone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomised trials.J Clin Oncol 1998: 16: 3832–42.Google Scholar
- 13.Durie BGM, Kyle RA, Belch A et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.The Haematol J 2003; 4: 379–398.Google Scholar
- 19.Kumar, Lacy MQ, Dispenzieri A et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. 2004 May 10 (epub ahead of print).Google Scholar
- 20.Cottler-Fox MH, Lapidot T, Petit I et al. Stem Cell Mobilization. ASH Education Book:Hematology 2003: 419–437.Google Scholar
- 22.Steward AK, Vescio R, Schiller G et al. Purging of autologous peripheral blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: Results of a multicentre randomised controlled trial.J Clin Oncol 2001; 19: 3771–9.Google Scholar
- 23.Siegel D, Mehta J, Anaissie E et al. Prolonged immunosuppression after CD34+ or CD34+/Thy-1+/ Linselected autologous peripheral blood stem cell (PBSC) transplants. (Tx) for multiple myeloma. Blood 1997: 90 (Suppl 1): 112a.Google Scholar
- 25.Moreau P, Facon T, Attal M et al. Comparison of 200 mg/ m (2) melphalan and 8 Gy total body irradiation plus 140 mg/m (2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomised trial.Blood 2002 Feb 1; 99(3): 731–5.CrossRefPubMedGoogle Scholar
- 28.Terpos E, Apperley JF, Samson D et al. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single centre experience in 127 patients.Bone Marrow Transplant 2003; 31: 163–170.CrossRefPubMedGoogle Scholar
- 30.Rosen LS, Gordon D, Kaminski M et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomised, doubleblind, multicenter, comparative trial.Cancer. 2003 Oct 15; 98(8): 1735–44.CrossRefPubMedGoogle Scholar
- 33.Catley L and Anderson K. Strategies to improve the outcome of stem cell transplantation in multiple myeloma.The Haematol J 2004; 5: 9–23.Google Scholar